Lou, Yue Clare http://orcid.org/0000-0002-0340-2166
Rubin, Benjamin E.
Schoelmerich, Marie C. http://orcid.org/0000-0001-7679-0043
DiMarco, Kaden S.
Borges, Adair L. http://orcid.org/0000-0002-1477-7908
Rovinsky, Rachel
Song, Leo http://orcid.org/0000-0003-4498-9722
Doudna, Jennifer A. http://orcid.org/0000-0001-9161-999X
Banfield, Jillian F. http://orcid.org/0000-0001-8203-8771
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (RAI092531A)
Article History
Received: 1 August 2023
Accepted: 6 November 2023
First Online: 16 November 2023
Competing interests
: The Regents of the University of California have a patent pending related to this work on which Y.C.L., B.E.R., A.L.B., and J.F.B. are inventors. J.F.B. is a co-founder of Metagenomi. J.A.D. is a co-founder of Caribou Biosciences, Editas Medicine, Scribe Therapeutics, Intellia Therapeutics, and Mammoth Biosciences. J.A.D. is a scientific advisory board member of Vertex, Caribou Biosciences, Intellia Therapeutics, Scribe Therapeutics, Mammoth Biosciences, The Column Group, and Inari. J.A.D. is a Director at Johnson & Johnson, Altos Labs, and Tempus and has research projects sponsored by AppleTree Partners and Roche. B.E.R. is a shareholder of Caribou Biosciences, Intellia Therapeutics, Locus Biosciences, Inari, TreeCo, and Ancilia Biosciences. The authors declare no competing interests.